A new drug to treat triple-negative breast cancer is ready to undergo testing.
A group of 15 genes responsible for accelerating the growth of cancer has been found by researchers at the Dana-Farber Cancer Institute in Boston.
This finding has paved the way for clinical trials on a drug which promises to retard or stop the development of triple-negative breast cancer tumors.
Currently, triple negative breast cancers affects more than 40,000 women annually. With these clinical trials, researchers are hoping to arrive at specific therapies to treat triple-negative breast cancers effectively.